Rami Komrokji, MD

Komrokji, Rami_4734.jpg
Position / Title
Clinical Director, Malignant Hematology Department Lead Clinical Investigator, MDS Program
Institution
H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida
Online Profile
https://www.moffitt.org/research-science/researchers/rami-komrokji/
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Practice Location

H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida
Tampa, FL
United States

Other pages on our site that mention Rami Komrokji:

  1. Research Article - A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study
  2. Research Article - A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study
  3. Research Article - Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study
  4. Conference Event - 2026 Tampa Patient and Family Conference
  5. Article - Study supports frontline use of imetelstat for low-risk MDS patients ineligible for ESAs
  6. Article - How I Treat Higher-Risk MDS with Alain Mina, Rami S. Komrokji
  7. Sectioned page - Patient and Family Conferences
  8. Research Article - Luspatercept in the treatment of lower-risk myelodysplastic syndromes
  9. Research Article - Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
  10. Research Article - TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
  11. Research Article - Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)
  12. Research Article - SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes
  13. Research Article - Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure
  14. Research Article - Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL)
  15. Basic page - Medical Advisory Board